Following an extensive collaboration window involving design, regulatory licensing, manufacturing, planning, and installation, the Molybdenum-99 Target Delivery System at Darlington Unit 2, led by Laurentis Energy Partners and BWXT Medical Ltd., has officially reached the system energization milestone, enabling preliminary testing of the partially installed system.

The Tc-99m Generator program kicked off in 2018 with the design of a specialized system at BWXT’s facility in Peterborough that would enable the production of Mo-99 at Ontario Power Generation’s Darlington Nuclear Generating Station. In 2021, regulatory approval of the necessary license from the Canadian Nuclear Safety Commission was obtained, enabling the future production of this life-saving isotope. The balance of the system is scheduled for installation, and full system commissioning at Darlington in late 2022.

In preparation for Q4 2022, when the remaining components of the Mo-99 system will be installed, the team has started preliminary testing to confirm the functionality of the equipment currently installed.

On behalf of BWXT Medical, Laurentis is overseeing this project at Darlington. When the production system is operational and has obtained FDA and Health Canada approval, BWXT’s Peterborough operations will manufacture and deliver the molybdenum targets to Darlington for irradiation. Once the targets are irradiated, BWXT Medical will then process the Mo-99 and integrate it into Tc-99m generators.

To read more please visit:

 One step closer to producing the life-saving Molybdenum-99 Isotope at Darlington

Source: Laurentisenergy